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Abstract
Background: Targeting abnormal DNA methylation represents a therapeutically relevant strategy for cancer
treatment as demonstrated by the US Food and Drug Administration approval of the DNA methyltransferase
inhibitors azacytidine and 5-aza-2’-deoxycytidine for the treatment of myelodysplastic syndromes. But their use is
associated with increased incidences of bone marrow suppression. Alternatively, procainamide has emerged as a
potential DNA demethylating agent for clinical translation. While procainamide is much safer than 5-aza-2’-
deoxycytidine, it requires high concentrations to be effective in DNA demethylation in suppressing cancer cell
growth. Thus, our laboratories have embarked on the pharmacological exploitation of procainamide to develop
potent DNA methylation inhibitors through lead optimization.
Methods: We report the use of a DNA methylation two-component enhanced green fluorescent protein reporter
system as a screening platform to identify novel DNA methylation inhibitors from a compound library containing
procainamide derivatives.
Results: A lead agent IM25, which exhibits substantially higher potency in GSTp1 DNA demethylation with lower
cytotoxicity in MCF7 cells relative to procainamide and 5-aza-2’-deoxycytidine, was identified by the screening
platform.
Conclusions: Our data provide a proof-of-concept that procainamide could be pharmacologically exploited to
develop novel DNA methylation inhibitors, of which the translational potential in cancer therapy/prevention is
currently under investigation.
Background
As DNA methylation-mediated silencing of genes has
been implicated in the pathogenesis of many diseases
including cancer [1-7], targeting aberrant DNA methyla-
tion is considered as a therapeutically relevant strategy for
cancer treatment. Among many agents with DNA methy-
lation-modifying capability, 5-aza-2’-deoxycytidine (decita-
bine; 5-Aza) is the best-known DNA demethylation agent.
5-Aza exerts its effect by inhibiting DNA methyltrans-
ferases (DNMTs), the key enzymes responsible for initiat-
ing or maintaining the DNA methylation status, thereby
facilitating the re-expression of tumor suppressor genes
through DNA hypomethylation. Its therapeutic efficacy is
manifest by the Food and Drug Administration approval
for the treatment of myelodysplastic syndromes. While
5-Aza is a potent DNA demethylation agent [8,9], its use
is associated with increased incidences of bone marrow
suppression, including neutropenia and thrombocytopenia,
due to the disruption of DNA synthesis. In addition,
shorter half-life hinders the effective delivery of 5-Aza to
the tumor site [10].
Recently, procainamide has emerged as a potential
DNA demethylating agent for clinical translation. Evi-
dence indicates that procainamide inhibits DNMT1 by
reducing the affinity with its two substrates: hemimethy-
lated DNA and S-adenosylmethionine [11-13]. Through
DNA demethylation, procainamide causes growth arrest
[9] and reactivation of tumor suppressor genes in cancer
cells [14]. Moreover, as an anti-arrhythmic drug, procai-
namide has a well-characterized safety profile without
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gues [15,16]. However, in contrast to 5-Aza, procaina-
mide requires high concentrations (≥ 50 μM) to be
effective in DNA demethylation in suppressing cancer
cell growth [9,11]. Thus, our laboratories have embarked
on the pharmacological exploitation of procainamide to
develop potent DNA methylation inhibitors through
lead optimization.
Previously, we reported a two-component enhanced
green fluorescent protein (EGFP) reporter gene system
for the visualization and quantization of dynamic
changes in targeted DNA methylation in bone marrow-
derived mesenchymal stem cells or cancer cell lines
[17,18]. This system gives a direct and concomitant
measurement and evaluation of DNA demethylation and
cytotoxicity in living cells, thus providing an expedient
screening platform for identifying demethylating agents.
As the exact mode of action of procainamide in decreas-
ing the binding DNMT1 with its substrate remains
undefined, we used procainamide as a scaffold to
develop a focused compound library, which in combina-
tion with other in-house compound libraries, was used
for screening via this two-component system.
Methods
Cell culture and drug treatment
MCF7 breast cancer cells, obtained from American Type
Culture Collection, were grown in Minimal Essential Med-
ium (MEM; Invitrogen), supplemented with 10% FBS,
2 mM L-glutamine, and 100 μg/ml penicillin/streptomy-
cin. Cells were cultured at 37°C in a humidified incubator
containing 5% CO2. Medium changes were performed
twice weekly and cell passages were performed at 90%
confluence. To maintain the two-component constructs in
MCF7 cells, 200 μg/mL of hygromycin B (Invitrogen) and
500 μg/mL of Geneticin (G418, Calbiochem) were
included in culture medium. 5-Aza and procainamide
were purchased from Sigma-Aldrich. Synthesis of procai-
namide derivatives and other tested agents (structures,
Additional file 1: Figure S1) will be described elsewhere.
Tested agents were dissolved in DMSO as stock solutions,
and added to culture medium with final DMSO concen-
trations of 0.3% and 1.2% (v/v) for 7.5 μMa n d3 0μMo f
testing drugs, respectively. Control cells received DMSO
vehicle. During the 5-day treatment period, medium was
changed on the third day of treatment along with the addi-
tion of 17b-estrodial (E2, 10 ng/ml).
In vitro DNA methylation
PCR-amplified and purified Trip10 promoter (4 μg) was
incubated with 20 U of CpGm e t h y l t r a n s f e r a s e( SssI,
New England BioLabs) at 37°C for 4 h in the presence
of 160 μM S-adenosylmethionine to induce methylation
at the Trip10 promoter DNA. Complete conversion was
indicated by the resistance of methylated Trip10 DNA
to methylation-sensitive restriction enzymes (HpaII,
New England BioLabs).
Transfection
In vitro methylated Trip10 promoter DNAs (0.4 μg) were
denatured and used to transfect 1 × 10
5 cells/well in 6-well
plate at day 1, 3, and 5 using DMRIE-C (Invitrogen)
according to the manufacturer’s instruction. Unmethylated
PCR products were transfected as mock controls. Tracking
of the transfected DNAs was performed by using the Labe-
lIT Tracker Cy5 Intracellular Nucleic Acid Localization Kit
(Mirus) by following the manufacture’s instruction. Cells
were monitored by fluorescence microscopy (Axiovert
200M, ZEISS) and analyzed with the MetaMorph software.
Bisulfite conversion
Genomic DNA (0.5 μg) was bisulfite-converted by the
EZ DNA Methylation Kit (Zymo) by following the man-
ufacturer’s instruction.
Qmsp
Bisulfite converted DNAs were PCR-amplified by using
PCR primers listed in Additional file 1: Table S1. Uni-
versal methylated DNAs (Millipore) were used as posi-
tive control. Col2A1 w a su s e da sal o a d i n gc o n t r o la n d
to amplify the serial diluted (1/10, 1/100 and 1/1000)
bisulfite-converted universal methylated DNAs to gener-
ate the standard curve for quantization in real time PCR
machine (Bio-Rad, iQ5). The methylation percentage
was calculated as [(Intensity of Amplifications by Trip10
MSP primer set) × 100]/(Intensity of Amplifications by
Col2A1 MSP primer set) (%). The qMSP was performed
in a 25 μL of reaction mixture containing 4 μLo ft e m -
plate (bisulfite treated DNA), 2 μLo fp r i m e rp a i r( 2 . 5
μM), 12.5 μL of 2X reaction buffer (SYBR Green real
time PCR Master Mix, Toyobo), and 6.5 μLo fH 2O.
Analysis of EGFP expression was performed by
fluorescence microscopy (Axiovert 200M, ZEISS) with
the MetaMorph software. Images and intensities of
EGFP of more than 600 cells were analyzed by the
image analysis program NIH Image (Image J).
Western blotting
Equal amounts of protein in cell lysates were separated
in 10% SDS polyacrylamide gels and then transblotted
to nitrocellulose membranes. After blocking with non-
fat milk, the membrane was washed and incubated with
antibodies against GFP (Abcam) or b-actin (Sigma-
Aldrich). The membrane was washed, and then incu-
bated with anti-rabbit immunoglobulin G-horseradish
peroxidase. After final wash, the proteins were visualized
by enhanced chemiluminescence. Immunoblotting data
were analyzed by NIH Image.
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Cell viability was assessed using MTT [3-(4,
5-dimethylthiazol- 2-yl)-2,5-diphenyl-2H-tetrazolium
bromide, Sigma-Aldrich) in six replicates. MCF7 cells
were seeded at 4,000 cells per well in 96-well plates, and
treated with test agents at different concentrations. After
5-day treatment, cells were incubated in medium con-
taining 0.5 mg/ml MTT at 37°C for 4 h. Reduced MTT
was solubilized in 200 μl/well of DMSO for determina-
tion of absorbance of 595 nm using a microplate reader.
ELISA
Enzyme-linked immunosorbent assay (ELISA) was per-
formed using the GFP ELISA kit (Cell Biolabs, San
Diego, CA) according to the manufacture’s instruction.
Differential Methylation Hybridization (DMH) Array
DMH was performed according to a reported procedure
[19]. Amplicons prepared from control (vehicle-treated)
MCF7 cells were labeled with Cy5 and the amplicons
prepared from drug-treated cells were labeled with Cy3.
Labeled DNAs were co-hybridized onto 244K Agilent
promoter array. Array hybridization results were nor-
malized with LOWESS and a cutoff of 4 folds was used.
Statistics
ELISA and MTT results were analyzed by F-test. Signifi-
cant demethylated loci were confirmed by ANOVA
from DMH results. Linear regression was used to
deduce the global methylation states before and after
the demethylation agent treatment.
Results
Monitoring DNA methylation status by a two-component
EGFP reporter gene system
We previously reported the development of a two-com-
ponent EGFP reporter gene system to confirm the level
of transcriptional silencing and to visualize DNA methy-
lation of the Trip10 promoter in the differentiation of
bone marrow-derived mesenchymal stem cells [17]. In
this study, we further applied this DNA methylation-tar-
geted reporter system for the screening of compound
libraries to identify novel DNA methylation inhibitors.
As illustrated in Figure 1A, the system consists of two
constructs. The first construct consists of the CpG-rich
Trip10 promoter region, which governs the expression
of downstream Tet repressor. The Trip10 promoter also
contains an estrogen receptor (ER)-binding site, which is
e s s e n t i a lf o rt h eg e n ee x p r e ssion in ER-positive MCF7
breast cancer cells. The second construct contains two
Tet repressor-binding sites, Tet operator (TetO2), which
is located between the viral CMV promoter and the
EGFP reporter gene. When the Trip10 promoter in the
first construct was un-methylated, the expressed Tet
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Figure 1 Screening system for demethylation agents.
(A) Schematic depiction of the reporter system in MCF7 cells. The
reporter gene system consists of two constructs (top). Expression of
Tet repressor (TetR) was under the regulation of Trip10 promoter.
The addition of doxycycline (Dox) or targeted methylation of Trip10
promoter (center) blocks the silencing/binding of Tet repressor onto
the Tet operator (TetO2) thus the EGFP would express and become
detectable with fluorescence microscope. Bottom, demethylation of
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to the TetO2. Conversely, methylation of Trip10 promo-
ter would suppress the expression of Tet repressor and
thus de-repress the EGFP expression. These two con-
structs were co-transfected into MCF7 cells, and trans-
fectants containing both constructs were selected by
hygromycin and G418 and confirmed by PCR. To vali-
date the co-transfection and the two-component regula-
tion, doxycycline (Dox) was added to interfere with the
expressed Tet repressor and de-repress the EGFP
expression (Figure 1B). To examine the transfection effi-
ciency, the in vitro methylated Trip10 (me_Trip10)
DNAs were coupled with Cy5 and then transfected into
the MCF7 cells. Our data indicate a strong correlation
between Cy5-expression and EGFP expression in these
cells (Figure 1C), suggesting high transfection efficiency.
We further validated this two-component EGFP
reporter gene system by exposing the transfected
MCF7 cells to different concentrations of 5-Aza and
procainamide. After 5-day treatment, both agents
showed dose-dependent, repressive effects on EGFP
expression levels relative to DMSO control, as visua-
lized by fluorescence microscopy, with relative potency
of 5-Aza greater than procainamide (Additional file 1:
Figure S2 and Figure 2B). Equally important, as these
two drugs did not cause morphological changes [light
microscopy (Vis), Additional file 1: Figure S2] or
suppression of cell viability (Figure 3A, Statistics in
Additional file 1: Table S2), these findings indicate that
this reduction in EGFP expression was not caused by
drug-induced cell death, suggesting a direct conse-
quence of DNA demethylation.
Screening of a compound library using the two-
component reporter system
After validating this reporter system, we set to assess the
abilities of individual compounds in our compound
library, each at 7.5 μM, to mediate DNA demethylation.
This library consisted of 169 compounds, the majority
of which were procainamide derivatives (Additional file
1: Figure S1). Based on this screening platform, 46 deri-
vatives significantly inhibited EGFP expression, of which
36 did not cause apparent cell death (Additional file 1:
Figure S3). Interestingly, these 36 compounds belonged
t ot h r e es t r u c t u r a ls e r i e s ,i . e . ,I M ,C I ,a n d4 x ,o fw h i c h
IM25, CI-4-1, and 4e (structures, Figure 2A) represented
optimal agents. The dose-responses of these agents,
along with three structurally related analogues IM9, CI-
5-1 and 4o, in suppressing EGFP expression are
depicted in Figure 2B.
These agents vis-à-vis 5-Aza and procainamide were
further subjected to ELISA (statistics in Additional file
1: Table S3) and Western blotting to assess their abil-
ities to suppress EGFP expression as well as MTT assays
(statistics in Additional file 1: Table S2) for their
the Trip10 promoter restores the expression of Tet repressor and
thus silences the EGFP. Open circles: unmethylated CpG
dinucleotides; filled circles: methylated CpG dinucleotides.
(B) Validation of the reporter gene system. As shown, presence of
doxycycline did not affect the cell density, but increased the
intensity of EGFP substantially (top). Histograms show the quantified
EGFP intensity in the presence or absence of doxycycline (bottom).
The EGFP intensity was analyzed and quantified by Image
J. Columns, mean (n = 3); error bars, S.D. (C) Tracking of the
transfected me_Trip10 DNAs. In vitro methylated Trip10 promoter
DNAs were labelled with or without (control) Cy5 and then used to
transfect the MCF7 cells. There is a high degree of overlap between
the EGFP-expressing cells and Cy5-positive cells, suggesting the high
transfection efficiency in this system.
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Figure 2 Identification of optimal DNA demethylating agents.
(A) Chemical structures of procainamide, the three selected agents
IM25, CI-4-1, and 4e and their structurally related analogues IM9, CI-
5-1, and 4o. (B) Potencies of procainamide, IM25, IM9, C-4-1, CI-5-1,
4e, and 4o in attenuating EGFP expression in the two-component
reporter system. The EGFP intensities in individual treatments are
illustrated on the right. Columns, mean (n = 3); error bars, S.D.
Lin et al. Journal of Biomedical Science 2011, 18:3
http://www.jbiomedsci.com/content/18/1/3
Page 4 of 8respective cytotoxicity. As revealed in Figure 3A and,
only 5-Aza, 4e, and 4o at high concentrations (30 μM)
substantially suppressed MCF7 cell viability, while other
compounds examined had no apparent effect (statistic
in Additional file 1: Table S2). Data obtained from
ELISA assay support the visualization results in Figure 2B,
in which IM25 exhibits greater demethylation potency
than 5-Aza in terms of inhibiting the EGFP expression.
In another set of experiment, cells were treated with
7.5 μM of candidate drugs for 5 days, then the cell
lysates were harvested and subjected to Western blot.
A ss h o w ni nF i g u r e3 C ,t h ep r o t e i nl e v e lo fE G F Pw a s
substantially suppressed by IM25 as well. However, we
did notice that the protein level appears to be
significantly inhibited by IM9 as well. The inconsistence
between the Western blot results versus the ELISA/
images is not immediately clear. Results obtained from
ELISA and Western blot confirmed that IM25 is an
effective demethylation agent in inhibiting EGFP
expression.
Targeted and global loci demethylation
Both 5-Aza and procainamide have been shown to cause
demethylation of GSTp1 (GSTπ1) in colon, prostate, and
breast cancer cells [11-14]. Thus, we conducted MSP to
determine the DNA methylation levels of Trip10 and
GSTp1 in MCF7 cells treated with IM25, CI-4-1, and 4e
vis-à-vis 5-Aza and procainamide. Among these testing
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Figure 3 Potency and safety of DNA demethylating agents. (A) Comparison of the dose-dependent suppressive effects of 5-Aza,
procainamide, IM25, and IM9 on the viability of MCF7 cells by MTT assays. Columns, mean (n = 3); error bars, S.D. (B) Parallel ELISA analysis of
the suppressive effects on EGFP expression in the two-component reporter system. Columns, mean (n = 3); error bars, S.D. (C) Western blot
analysis of the effects of procainamide, 5-Aza, IM9, and IM25, each at 7.5 μM, on EGFP expression.
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Page 5 of 8compounds, IM25 exhibits the greatest potency in facili-
tating the demethylation of both Trip10 and GSTp1, CI-
4-1 also decreases the methylation level of both genes,
but to a lesser extent (Figure 4A). Compound 4e showed
a slight demethylation of GSTp1 only at 30 μM. IM25
was chosen to further elucidate its genome-wide
demethylation effects. Cells treated with either IM-25 or
DMSO were harvested and subjected to DMH. As
demonstrated in Figure 4B, IM25 was able to cause glo-
bal demethylation in MCF7 cells. When comparing the
global demethylation capacity between IM25 and 5-Aza,
5,506 more demethylated loci out of 244K target loci in
Agilent array were identified (Figure 4C, significant loci
confirmed by ANOVA). Therefore, the identified IM25
possesses equal or more demethylation capacity than
the known drugs such as 5-Aza and procainamide.
Discussion
Since the discovery that DNA methylation-mediated gene
silencing is a reversible event, identifying small-molecule
DNA methylation inhibitors, either natural or synthetic,
for cancer treatment has been the focus of many investi-
gation [10]. Although 5-Aza is the most potent demethy-
lating agent in clinical use, general side effects associated
with this nucleoside drug such as bone marrow suppres-
sion might be of concern. Thus, continuing efforts have
been made to search for additional DNA methylation
inhibitors with greater potency but low cytotoxicity. Pro-
cainamide, anti-arrhythmic drug, has emerged as a
potential candidate because of its well-characterized
safety profile. However, its clinical translation might be
hindered by its relatively low potency in inhibiting DNA
methylation. Thus, our laboratories have embarked on
the pharmacological exploitation of procainamide to
identify novel DNA demethylating agents through the
unique screening platform we have developed.
In the present study, IM25, a procainamide derivative,
is found to be as potent as 5-Aza in terms of demethyla-
tion but with much lower cytotoxicity. Azacytidine and
5-Aza have been approved for the treatment of myelo-
dysplastic syndromes by FDA, and they are currently
under clinical trials for treatment of solid tumors
including breast cancer, lung cancer, and colon cancer
[20-28]. On the other hand, accumulating data indicate
that these demethylation agents could also control stem
cell differentiation [29] and treat diseases like sickle cell
disease [30]. Despite these promising clinical and in
vitro studies for cancer treatment and cell fate manipu-
lation, the side effects such as bone marrow suppression
has always been a great concern. Our global demethyla-
tion analysis by DMH and single target gene validation
by MSP indicate that IM25 treatment could disturb
MCF7 cell’s epigenome. However, IM25 did not cause
overt cell death even at rather high concentrations. We
A
B
Unaffected loci
Demethylated loci
Demethylated but not significantly
-2
0
2
4
6
8
Loci
L
o
g
2
[
C
y
5
/
C
y
3
]
Methylation (%)
Trip10 GSTS
DMSO
Proc.
5-Aza
IM25
IM9
CI-4-1
CI-5-1
4e
4o
05 0 100 150 05 0 100 150
05 0 100 150
05 0 100 150
05 0 100 150
05 0 100 150
05 0 100 150
0 50 100 150
0 50 100 150
0 50 100 150
05 0 100 150
05 0 100 150
05 0 100 150
05 0 100 150
0 50 100 150
0 50 100 150
05 0 100 150
0 50 100 150
0
7.5 30
Conc. (PM)
C
Figure 4 Drug-induced loci-specific and global demethylation.
(A) MSP was applied to determine the methylation level of Trip10
and GSTp1 in MCF7 cells treated with each of the following
derivatives at 7.5 or 30 μM: procainamide, 5-Aza, IM25, IM9, CI-4-1,
CI-5-1, 4e, and 4o, after 5 days of treatment. Procainamide, 5-Aza,
IM25, CI-4-1 and 4e significantly reduced the methylation level of
GSTp1, while they appear to have weaker effect in demethylating
Trip10 promoter (B) DMH analysis of the effect of 7.5 μM IM25 on
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gene expression profile and subsequently cause changes
in cell physiology/behaviour without affecting cell viabi-
lity. It will be crucial to determine if IM25 has the same
demethylation potency and safety in other cancer cell
types or stem cells. In addition, to determine the IM25’
effect in an animal model system will provide in-depth
information regarding its efficacy and safety upon sys-
temic administration, which can serve as justification for
its future clinical application as a direct antitumor drug,
an adjuvant, or other therapeutic uses.
On the other hand, present study also demonstrates
the feasibility of the established two-component reporter
system as an efficient drug screening platform in live
cells. While the efficacy of 5-Aza in reducing GSTp1
methylation is lower in the two-component system than
in the MSP assay, which possibly is attributed to the
engineered two-component stable clones, we reason that
the direct, non-invasive measurement and comparisons
of testing drugs in the two-component platform can
serve as a powerful while economic tool for rapid drug
screening at preclinical stage.
Conclusions
In summary, the impetus of this study is twofold. First,
our DNA methylation-targeted two-component reporter
system represents an expedient screening platform to
identify agents with DNA methylation-altering capabil-
ity. Second, we have identified the procainamide deriva-
tive IM25 which exhibits high global demethylation
potency, of which the translational value in cancer treat-
ment represents the focus of this investigation.
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